Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and is associated with a dismal median survival of 2–9 months. The fundamental limitations and ineffectiveness of current HCC treatments have led to the development of a vast range of nanotechnologies with the goal of...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI AG
2021-12-01
|
| Col·lecció: | Pharmaceutics |
| Matèries: | |
| Accés en línia: | https://www.mdpi.com/1999-4923/14/1/41 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|